Nama's AI scorecard currently rates Rhythm Pharmaceuticals Sell (3.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does RYTM report earnings?

Rhythm Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.73.

What is the RYTM price target?

The median analyst price target from 17 analysts is $143.00, with a range of $120.00 – $160.00.

Is RYTM Shariah compliant?

Nama's AAOIFI-style screen reads Rhythm Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Rhythm Pharmaceuticals (RYTM)

Healthcare · Biotechnology · NASDAQ

Rhythm Pharmaceuticals (RYTM) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $7.78B and a free-cash-flow yield of -1.6%. Over the most recent reported fiscal year, revenue grew 45.8%. Nama's AI scorecard rates it Sell, 3.9 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.9/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -10.2% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-8.1%

How far the last close sits under the highest price of the past five years.

Market cap	$7.78B
Trailing P/E	—
Price / book	35.5
Price / sales	32.3
FCF yield	-1.6%
Dividend yield	—
Gross margin	89.0%
Operating margin	-83.6%
Net margin	-85.6%
Revenue growth (YoY)	+45.8%
Revenue growth (3-yr annual)	+100.2%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

RYTM earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.73). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	-$0.61	-$0.74	+17.6%	$92.13M
Q2 2026	Aug 4, 2026	-$0.73	-$0.83	+12.1%	$71.25M
Q1 2026	May 5, 2026	-$0.83	-$0.86	+3.5%	$60.11M
Q4 2025	Feb 26, 2026	-$0.73	-$0.78	+6.4%	$57.25M

RYTM analyst price target

Median target $143.00 from 17 analysts, ranging $120.00 – $160.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live RYTM data on Nama Insights →

RYTM FAQ

Is RYTM a buy?: Nama's AI scorecard currently rates Rhythm Pharmaceuticals Sell (3.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does RYTM report earnings?: Rhythm Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.73.
What is the RYTM price target?: The median analyst price target from 17 analysts is $143.00, with a range of $120.00 – $160.00.
Is RYTM Shariah compliant?: Nama's AAOIFI-style screen reads Rhythm Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.